Department of Pathology, Oslo University Hospital-Radiumhospitalet, Oslo, Norway.
Department of Molecular Oncology, Institute for Cancer Research, Oslo University Hospital-Radiumhospitalet, Oslo, Norway.
Histopathology. 2023 Dec;83(6):853-869. doi: 10.1111/his.15012. Epub 2023 Jul 28.
A cribriform pattern, reactive stroma (RS), PTEN, Ki67 and ERG are promising prognostic biomarkers in primary prostate cancer (PCa). We aim to determine the relative contribution of these factors and the Cancer of the Prostate Risk Assessment Postsurgical (CAPRA-S) score in predicting PCa prognosis.
We included 475 patients who underwent radical prostatectomy (2010-12, median follow-up = 8.7 years). Cribriform pattern was identified in 57% of patients, PTEN loss in 55%, ERG expression in 51%, RS in 39% and high Ki67 in 9%. In patients with multiple samples from the same malignant focus and either PTEN loss or high Ki67, intrafocal heterogeneity for PTEN and Ki67 expression was detected in 55% and 89%, respectively. In patients with samples from two or more foci, interfocal heterogeneity was detected in 46% for PTEN and 6% for Ki67. A cribriform pattern and Ki67 were independent predictors of biochemical recurrence (BCR) and clinical recurrence (CR), whereas ERG expression was an independent predictor of CR. Besides CAPRA-S, a cribriform pattern provided the highest relative proportion of explained variation for predicting BCR (11%), and Ki67 provided the highest relative proportion of explained variation for CR (21%). In patients with a cribriform pattern, high Ki67 was associated with a higher risk of BCR [hazard ratio (HR) = 2.83, P < 0.001] and CR (HR = 4.35, P < 0.001).
High Ki67 in patients with a cribriform pattern identifies a patient subgroup with particularly poor prognosis, which we termed 'high proliferative cribriform prostate cancer'. These results support reporting a cribriform pattern in pathology reports, and advocate implementing Ki67.
在原发性前列腺癌(PCa)中,筛状模式、反应性基质(RS)、PTEN、Ki67 和 ERG 是有前途的预后生物标志物。我们旨在确定这些因素以及前列腺癌术后风险评估(CAPRA-S)评分在预测 PCa 预后中的相对贡献。
我们纳入了 475 名接受根治性前列腺切除术(2010-12 年,中位随访时间=8.7 年)的患者。57%的患者存在筛状模式,55%的患者存在 PTEN 缺失,51%的患者存在 ERG 表达,39%的患者存在 RS,9%的患者 Ki67 高表达。在同一恶性病灶有多个样本且存在 PTEN 缺失或 Ki67 高表达的患者中,PTEN 和 Ki67 表达的灶内异质性分别在 55%和 89%的患者中检测到。在有两个或更多病灶样本的患者中,PTEN 的灶间异质性在 46%的患者中检测到,Ki67 的灶间异质性在 6%的患者中检测到。筛状模式和 Ki67 是生化复发(BCR)和临床复发(CR)的独立预测因素,而 ERG 表达是 CR 的独立预测因素。除了 CAPRA-S,筛状模式对预测 BCR(11%)的变异解释比例最高,Ki67 对预测 CR(21%)的变异解释比例最高。在存在筛状模式的患者中,高 Ki67 与 BCR(危险比[HR]=2.83,P<0.001)和 CR(HR=4.35,P<0.001)的风险增加相关。
在存在筛状模式的患者中,高 Ki67 确定了预后特别差的患者亚组,我们称之为“高增殖性筛状前列腺癌”。这些结果支持在病理报告中报告筛状模式,并提倡实施 Ki67。